Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

NCT ID: NCT07326657

Last Updated: 2026-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

PHASE4

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized controlled clinical trial is to determine whether use of Kericis Intact Fish Skin Graft (IFSG) can decrease the amount of autograft tissue needed for treatment of deep partial-thickness burns in patients at least 18 years of age with a deep partial-thickness burn for whom autograft treatment is clinically indicated. This clinical trial seeks to collect the following:

1. Difference in the percentage area of the IFSG treatment site and control autograft treatment site that required autografting within 1 month of treatment
2. Proportion of subjects achieving durable wound closure of the IFSG treatment site without autograft placement within 2 months of treatment
3. Difference in cosmesis between the IFSG treatment site and autograft treatment site a year after treatment
4. Difference in the pain intensity between the IFSG treatment site and autograft treatment site

Each participant will receive autograft and intact fish skin graft (IFSG) on different areas of their deep partial-thickness burn. Participants will be assessed for the need for further autograft treatment. Participants will also be assessed for wound closure, pain, and cosmesis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Partial-thickness Burn Wounds

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The intervention study model is a split-body intervention in which each patient has part of their burn treated with intact fish skin graft and another part treated with autograft as the standard-of-care.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IFSG-Treated Area of Burn

The area of the deep partial-thickness burn that is treated with IFSG

Group Type EXPERIMENTAL

Intact fish skin graft

Intervention Type DEVICE

Treatment with IFSG

SOC Autograft-Treated Area of Burn

The area of the deep partial-thickness burn that is treated with autograft as standard-of-care

Group Type ACTIVE_COMPARATOR

autograft

Intervention Type PROCEDURE

Treatment with autograft

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intact fish skin graft

Treatment with IFSG

Intervention Type DEVICE

autograft

Treatment with autograft

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 18 years of age at time of consent
2. Must have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated.
3. Be able to provide written informed consent or have a legally authorized representative
4. Have sufficient healthy skin identified and designated as a potential donor site in the event that the IFSG treatment site requires autografting.
5. Investigator expects that the donor site will heal without grafting
6. Have a complex skin defect of 3 to 49% Total Body Surface Area, which can consist of more than one contiguous area

At the time of debridement:
7. Have thermal burn(s) with intact dermal elements for which excision and autografting are clinically indicated
8. Study treatment areas can be up to 2000 cm2
9. Must have at least 100 cm2 TBSA for which autografting is indicated and on which IFSG can be applied, which may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso
10. Application of IFSG or SOC must be initiated within 14 days of injury (Application of IFSG or SOC must be initiated within 14 days of injury)
11. Have first excision and grafting of study treatment sites
12. Have thermal burn(s) on the torso or extremities

Exclusion Criteria

1. Known allergy or hypersensitivity to fish (shellfish allergy is OK)
2. Female who is actively pregnant or currently breast-feeding
3. Vulnerable populations
4. Currently receiving systemic immunosuppressive therapy
5. Current or known history of malignancy or receipt of chemotherapy
6. History of Diabetes with documented uncontrolled diabetes (as defined by an A1C \>9) within the last 6 months
7. Have an expected survival of less than 3 months
8. Are currently participating/have participated in the treatment group of an interventional study within 90 calendar days prior to consent
9. Have other wounds present for \> 30 days

At the time of debridement:
10. Treatment area is assessed as full-thickness after debridement
11. Treatment areas on the face, neck, head, hands, feet, buttocks, perineum, and areas over joints (Treatment areas may only be on the torso or extremities)
12. Have a clinical or laboratory determination of infection at the anticipated treatment sites.

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Burn Association

OTHER

Sponsor Role collaborator

BData, Inc.

UNKNOWN

Sponsor Role collaborator

Kerecis Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loyola University Medical Center

Maywood, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KS-1040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microsurfaced Grafts in Deep Burn Wounds
NCT04589442 RECRUITING PHASE4